Skip to main content
Top
Published in: International Journal of Colorectal Disease 11/2010

01-11-2010 | Original Article

γ-Catenin is an independent prognostic marker in early stage colorectal cancer

Authors: Jutta Maria Nagel, Lydia Kriegl, David Horst, Jutta Engel, Shiva Gautam, Christos S. Mantzoros, Thomas Kirchner, Burkhard Göke, Frank Thomas Kolligs

Published in: International Journal of Colorectal Disease | Issue 11/2010

Login to get access

Abstract

Purpose

Expression and role of γ-catenin in colorectal carcinogenesis is not well understood. We aimed at characterizing γ-catenin’s expression pattern during colorectal carcinogenesis.

Methods

The expression pattern of γ-catenin was characterized in adenomas, primary colorectal carcinomas, and their corresponding metastases. Since this descriptive immunohistochemical analysis revealed upregulation of γ-catenin in the invasive front of both primary tumors and metastases, a tissue microarray (TMA) was performed, allowing for correlation of subcellular expression patterns with disease recurrence and cancer-specific survival. Comparison of γ-catenin expression with that of β-catenin was performed.

Results

In normal colonic epithelium and adenomas, γ-catenin was weakly expressed at the membrane. In central areas of primary colorectal carcinomas, membranous and cytoplasmatic expression was present, with cytoplasmatic and nuclear upregulation of γ-catenin in the invasive fronts. Expression patterns found in metastases resembled those of their respective primary tumors. Subsequent TMA analysis showed that upregulation of cytoplasmatic γ-catenin in the invasive fronts of curatively resected early T2 and T3 colorectal carcinomas was associated with shortened disease-free survival and an increased risk of death (p = 0.003; hazard ratio = 2.98; 95% confidence interval, 1.44–6.18).

Conclusions

The correlation of upregulated cellular γ-catenin levels with higher recurrences and impaired survival suggests a tumor promoting role of γ-catenin in colorectal cancer. γ-Catenin may therefore serve as a marker for identifying patients who are at increased risk of disease recurrence who may benefit from closer follow-up and adjuvant therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kolligs FT, Bommer G, Goke B (2002) Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66:131–144CrossRefPubMed Kolligs FT, Bommer G, Goke B (2002) Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion 66:131–144CrossRefPubMed
2.
go back to reference Caca K, Kolligs FT, Ji X et al (1999) Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 10:369–376PubMed Caca K, Kolligs FT, Ji X et al (1999) Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 10:369–376PubMed
3.
go back to reference Kodama S, Ikeda S, Asahara T, Kishida M, Kikuchi A (1999) Axin directly interacts with plakoglobin and regulates its stability. J Biol Chem 274:27682–27688CrossRefPubMed Kodama S, Ikeda S, Asahara T, Kishida M, Kikuchi A (1999) Axin directly interacts with plakoglobin and regulates its stability. J Biol Chem 274:27682–27688CrossRefPubMed
4.
go back to reference Kolligs FT, Kolligs B, Hajra KM et al (2000) gamma-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 14:1319–1331PubMed Kolligs FT, Kolligs B, Hajra KM et al (2000) gamma-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 14:1319–1331PubMed
5.
go back to reference Maeda O, Usami N, Kondo M et al (2004) Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene 23:964–972CrossRefPubMed Maeda O, Usami N, Kondo M et al (2004) Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line. Oncogene 23:964–972CrossRefPubMed
6.
go back to reference Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797–3804CrossRefPubMed Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797–3804CrossRefPubMed
7.
go back to reference Shtutman M, Zhurinsky J, Oren M, Levina E, Ben-Ze’ev A (2002) PML is a target gene of beta-catenin and plakoglobin, and coactivates beta-catenin-mediated transcription. Cancer Res 62:5947–5954PubMed Shtutman M, Zhurinsky J, Oren M, Levina E, Ben-Ze’ev A (2002) PML is a target gene of beta-catenin and plakoglobin, and coactivates beta-catenin-mediated transcription. Cancer Res 62:5947–5954PubMed
8.
go back to reference Zhurinsky J, Shtutman M, Ben-Ze’ev A (2000) Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J Cell Sci 113(Pt 18):3127–3139PubMed Zhurinsky J, Shtutman M, Ben-Ze’ev A (2000) Plakoglobin and beta-catenin: protein interactions, regulation and biological roles. J Cell Sci 113(Pt 18):3127–3139PubMed
9.
go back to reference Zhurinsky J, Shtutman M, Ben-Ze’ev A (2000) Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol 20:4238–4252CrossRefPubMed Zhurinsky J, Shtutman M, Ben-Ze’ev A (2000) Differential mechanisms of LEF/TCF family-dependent transcriptional activation by beta-catenin and plakoglobin. Mol Cell Biol 20:4238–4252CrossRefPubMed
10.
go back to reference Miravet S, Piedra J, Miro F, Itarte E, de Garcia HA, Dunach M (2002) The transcriptional factor Tcf-4 contains different binding sites for beta-catenin and plakoglobin. J Biol Chem 277:1884–1891CrossRefPubMed Miravet S, Piedra J, Miro F, Itarte E, de Garcia HA, Dunach M (2002) The transcriptional factor Tcf-4 contains different binding sites for beta-catenin and plakoglobin. J Biol Chem 277:1884–1891CrossRefPubMed
11.
go back to reference Williams BO, Barish GD, Klymkowsky MW, Varmus HE (2000) A comparative evaluation of beta-catenin and plakoglobin signaling activity. Oncogene 19:5720–5728CrossRefPubMed Williams BO, Barish GD, Klymkowsky MW, Varmus HE (2000) A comparative evaluation of beta-catenin and plakoglobin signaling activity. Oncogene 19:5720–5728CrossRefPubMed
12.
go back to reference Simcha I, Shtutman M, Salomon D et al (1998) Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J Cell Biol 141:1433–1448CrossRefPubMed Simcha I, Shtutman M, Salomon D et al (1998) Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J Cell Biol 141:1433–1448CrossRefPubMed
13.
go back to reference Kolligs FT, Hu G, Dang CV, Fearon ER (1999) Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 19:5696–5706PubMed Kolligs FT, Hu G, Dang CV, Fearon ER (1999) Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 19:5696–5706PubMed
14.
go back to reference Polakis P (2000) Wnt signaling and cancer. Genes Dev 14:1837–1851PubMed Polakis P (2000) Wnt signaling and cancer. Genes Dev 14:1837–1851PubMed
15.
go back to reference Shiina H, Breault JE, Basset WW et al (2005) Functional loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 65:2130–2138CrossRefPubMed Shiina H, Breault JE, Basset WW et al (2005) Functional loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 65:2130–2138CrossRefPubMed
16.
go back to reference Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D, Ben-Ze’ev A (1996) Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol 133:199–209CrossRefPubMed Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D, Ben-Ze’ev A (1996) Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol 133:199–209CrossRefPubMed
17.
go back to reference Breault JE, Shiina H, Igawa M et al (2005) Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res 11:557–564PubMed Breault JE, Shiina H, Igawa M et al (2005) Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res 11:557–564PubMed
18.
go back to reference Winn RA, Bremnes RM, Bemis L et al (2002) gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 21:7497–7506CrossRefPubMed Winn RA, Bremnes RM, Bemis L et al (2002) gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 21:7497–7506CrossRefPubMed
19.
go back to reference Taal BG, Van TH, Zoetmulder FA (2001) Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 85:1437–1443CrossRefPubMed Taal BG, Van TH, Zoetmulder FA (2001) Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 85:1437–1443CrossRefPubMed
20.
go back to reference IMPACT-investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939–944CrossRef IMPACT-investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939–944CrossRef
21.
go back to reference Moertel CG, Fleming TR, Macdonald JS et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 13:2936–2943PubMed Moertel CG, Fleming TR, Macdonald JS et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 13:2936–2943PubMed
22.
go back to reference Moore HC, Haller DG (1999) Adjuvant therapy of colon cancer. Semin Oncol 26:545–555PubMed Moore HC, Haller DG (1999) Adjuvant therapy of colon cancer. Semin Oncol 26:545–555PubMed
23.
go back to reference Quasar Collaborative G, Gray R, Barnwell J et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029CrossRef Quasar Collaborative G, Gray R, Barnwell J et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029CrossRef
24.
go back to reference Schippinger W, Samonigg H, Schaberl-Moser R et al (2007) A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 97:1021–1027CrossRefPubMed Schippinger W, Samonigg H, Schaberl-Moser R et al (2007) A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 97:1021–1027CrossRefPubMed
25.
go back to reference O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425CrossRefPubMed O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425CrossRefPubMed
26.
go back to reference Hakimelahi S, Parker HR, Gilchrist AJ et al (2000) Plakoglobin regulates the expression of the anti-apoptotic protein BCL-2. J Biol Chem 275:10905–10911CrossRefPubMed Hakimelahi S, Parker HR, Gilchrist AJ et al (2000) Plakoglobin regulates the expression of the anti-apoptotic protein BCL-2. J Biol Chem 275:10905–10911CrossRefPubMed
27.
go back to reference Pan H, Gao F, Papageorgis P, Abdolmaleky HM, Faller DV, Thiagalingam S (2007) Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther 6:1638–1643CrossRefPubMed Pan H, Gao F, Papageorgis P, Abdolmaleky HM, Faller DV, Thiagalingam S (2007) Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression. Cancer Biol Ther 6:1638–1643CrossRefPubMed
28.
go back to reference Ghadimi BM, Behrens J, Hoffmann I, Haensch W, Birchmeier W, Schlag PM (1999) Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. Eur J Cancer 35:60–65CrossRefPubMed Ghadimi BM, Behrens J, Hoffmann I, Haensch W, Birchmeier W, Schlag PM (1999) Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. Eur J Cancer 35:60–65CrossRefPubMed
29.
go back to reference Gastaldi T, Bonvini P, Sartori F, Marrone A, Iolascon A, Rosolen A (2006) Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation. Carcinogenesis 27:1758–1767CrossRefPubMed Gastaldi T, Bonvini P, Sartori F, Marrone A, Iolascon A, Rosolen A (2006) Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation. Carcinogenesis 27:1758–1767CrossRefPubMed
30.
go back to reference Bondi J, Bukholm G, Nesland JM, Bukholm IR (2004) Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 112:49–56CrossRefPubMed Bondi J, Bukholm G, Nesland JM, Bukholm IR (2004) Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 112:49–56CrossRefPubMed
Metadata
Title
γ-Catenin is an independent prognostic marker in early stage colorectal cancer
Authors
Jutta Maria Nagel
Lydia Kriegl
David Horst
Jutta Engel
Shiva Gautam
Christos S. Mantzoros
Thomas Kirchner
Burkhard Göke
Frank Thomas Kolligs
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
International Journal of Colorectal Disease / Issue 11/2010
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-010-1046-y

Other articles of this Issue 11/2010

International Journal of Colorectal Disease 11/2010 Go to the issue